465 related articles for article (PubMed ID: 19371895)
1. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Urol; 2009 Jun; 181(6):2526-32. PubMed ID: 19371895
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
4. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
5. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
6. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.
Nash PA; Leibovitch I; Foster RS; Bihrle R; Rowland RG; Donohue JP
J Urol; 1998 Mar; 159(3):707-10. PubMed ID: 9474130
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
8. Growing teratoma syndrome: experience of a single institution.
Maroto P; Tabernero JM; Villavicencio H; Mesía R; Marcuello E; Solé-Balcells FJ; Sola C; Mora J; Algaba F; Pérez C; León X; López López JJ
Eur Urol; 1997; 32(3):305-9. PubMed ID: 9358218
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
11. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
12. Germ cell tumor associated primitive neuroectodermal tumors.
Ganjoo KN; Foster RS; Michael H; Donohue JP; Einhorn LH
J Urol; 2001 May; 165(5):1514-6. PubMed ID: 11342908
[TBL] [Abstract][Full Text] [Related]
13. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
15. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.
Steiner H; Peschel R; Janetschek G; Höltl L; Berger AP; Bartsch G; Hobisch A
Urology; 2004 Mar; 63(3):550-5. PubMed ID: 15028456
[TBL] [Abstract][Full Text] [Related]
17. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
18. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
19. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases.
Comiter CV; Kibel AS; Richie JP; Nucci MR; Renshaw AA
J Urol; 1998 Mar; 159(3):859-63. PubMed ID: 9474169
[TBL] [Abstract][Full Text] [Related]
20. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.
Steiner H; Zangerl F; Stöhr B; Granig T; Ho H; Bartsch G; Peschel R
J Urol; 2008 Oct; 180(4):1348-52; discussion 1352-3. PubMed ID: 18707723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
